Tohoku University. Research Profiles

LANGUAGE
  • Top
  • Life Sciences
  • Drug Development for Fundamental Treatment of Alzheimer's Disease

Drug Development for Fundamental Treatment of Alzheimer's Disease

update:2018-12-21
  • JAPANESE
  • INQUIRY
  • seed-98-1-en.jpg
NEXT
PREV
Features
<strong>Background: </strong>Alzheimer's disease (AD) is a neurodegenerative disorder with a large unmet medical need. Recently, our pilot clinical study suggested the possibility that 1-year oral administration of decocted nobiletin-rich Citrus reticulata peel could be of benefit for improving the cognition of patients with AD, with the following pharmacological features: 1) this Kampo medicine includes a large amount of nobiletin that can rescue the memory impairment and prevents hippocampal amyloid beta accumulation in APP-Tg mice, as originally reported by us, and 2) the medicine reversed impaired learning and memory to a greater degree than nobiletin in animal, to which sinensetin, another constituent contributes in large part.
<strong>Research plan:</strong> We thus try to identify endogenous molecules that can bind selectively to nobiletin and sinensetin in hippocampal neurons, and to further synthesize novel compounds that are capable of more potently improving learning and memory impairment in animals than both natural compounds.

Targeted Application(s)/Industry
Our research goal is discovery of the drugs for fundamental treatment of AD. I hope to conduct collaborative research with a willing company for a practical application of this technology in industry.

Researchers

Department of Pharmacotherapy, Graduate School of Pharmaceutical Sciences

YAMAKUNI, Tohru , Associate Professor
PhD

Keywords

List